07:00 Mon 18 Nov 2019
ReNeuron Group plc - Notification of Interim Results
|
AIM: RENE |
("
Notification of Interim Results
A meeting for analysts will be held at
To access a webcast of the analyst presentation, please log on to the following web address approximately 10 minutes before
https://webcasting.buchanan.uk.com/broadcast/5dcc32879535b1405a05b0bd
A recording of the presentation will be made available on
ENDS
Contacts:
ReNeuron |
+44 (0) 20 3819 8400 |
Olav Hellebø, Chief Executive Officer |
|
Michael Hunt, Chief Financial Officer |
|
Buchanan (UK Media/Investor Relations) |
+44 (0) 20 7466 5000 |
Mark Court, Tilly Abraham |
|
Claudia Styslinger, David Rosen |
+1 212 600 1902 |
|
|
Jonathan Senior, Stewart Wallace, Ben Maddison |
+44 (0) 20 7710 7600
|
N+1 Singer (Joint Broker) Aubrey Powell, James Moat, Mia Gardner |
+44 (0) 20 7496 3000 |
|
|
About ReNeuron
ReNeuron is a global leader in cell-based therapeutics, harnessing its unique stem cell technologies to develop 'off the shelf' stem cell treatments, without the need for immunosuppressive drugs. The Company's lead clinical-stage candidates are in development for the blindness-causing disease, retinitis pigmentosa, and for disability as a result of stroke. ReNeuron is also advancing its proprietary exosome technology platform as a potential delivery system for drugs that would otherwise be unable to reach their site of action. ReNeuron's shares are traded on the London AIM market under the symbol RENE.L. For further information visit www.reneuron.com.
This information is provided by RNS, the news service of the
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of...
FOR OUR FULL DISCLAIMER CLICK HERE